At the 2025 EULAR congress in Barcelona, Prof Dimitrios Boumpas presented a summary of the updated EULAR recommendations on the management of lupus nephritis (LN). The most significant change in the treatment paradigm of LN is that the historic standard of care (SOC) (i.e.
Read Article
JAK inhibitors have taken a beating over the last three years. The excitement and potential has been tempered by mounting cardiovascular safety concerns, but specifically in at-risk patients, compared to TNF inhibitors. Once the suggestion is made, though, the concern is powerful.
Read Article
Following the establishment of formal definitions for Difficult-to-Treat Rheumatoid Arthritis (D2T RA) by EULAR and Difficult-to-Manage axial Spondyloarthritis (D2M axSpA) by ASAS, the “Difficult” framework has now reached psoriatic arthritis (PsA).
Read Article
The diagnosis of axial spondyloarthritis (axSpA) is clinical, however, there are still unmet needs, particularly in the diagnosis of early disease and evaluation of disease activity and progression.
Read Article
Highlights from today included presentations on imaging in vasculitis, a debate on whether to treat high risk pre-clinical RA, and EULAR Recommendations on a) Treatment of interstitial lung disease (ILD); b) Physical Activity in people with arthritis; and c) EULAR disease activity score for antip
Read Article
A single center study shows HLA-B27 testing is often performed by both by rheumatologists and nonrheumatologists for a wide array of reasons and often along w
Guidelines differ on the early treatment of RA – ACR suggests not to use glucocorticoids (GC) and EULAR updated recommendations for RA treatment presented at #EULAR2025 continued to suggest early treatment with MTX and glucocorticoids (1).
Read Article
There is still a question I have a hard time answering with certainty when people living with rheumatoid arthritis ask me: Is there a higher risk of cancer that comes with the disease? Or with the treatments?
Read Article
This article was originally published March 31, 2025, and is being shared again this week as part of our In Case You Missed It series. Enjoy!
Dr. Jack Cush reviews highlights, trends and novel studies from EULAR 2025 in Barcelona from last week.
Read Article
It's easy to think that in our current world that we've done it all for rheumatoid arthritis, that there's nothing left to be done after b/tsDMARDs have become relatively widespread and accessible.
Read Article
Nerandomilast, an inhibitor of phosphodiesterase 4B, orally administered, is a new mechanism of action to treat lung fibrotic diseases.
Read Article
Saturday was the final day of EULAR, and included several lectures, but mostly late breaking abstracts and new EULAR guidelines - notably on Rheumatoid Arthritis and another on Interstitial Lung disease in connective tissue disorders. My favorite presentations included the following:
Read Article
I asked the EULAR twitter sphere how they feel about combination of Methotrexate (MTX) and Leflunomide (LEF). The opinions are differing so far, with 50% reporting prescribing this combination often while 50% are worried of side effects.
Read Article
This article was originally published February 13, 2025, and is being shared again this week as part of our In Case You Missed It series. Enjoy!
Read Article
This article was originally published April 7, 2025, and is being shared again this week as part of our In Case You Missed It series.
A comprehensive review in Rheumatology on intracranial giant cell arteritis (icGCA) stresses that GCA is both an intracranial and extracranial large vessel vasculitis, with the former having unique presentations, and outcomes.
Day 2 was a full agenda for those attending EULAR 2025 in Barcelona with sessions on the management of RA, Behcets, Lupus and Hand Osteoarthritis. Clinical overviews on MAS, Ehlers-Danlos, Difficult to treat RA and PsA offered a wide variety of options to rheumatologists.
Read Article
The longest studied drug for uveitis in SpA has been monocolonal TNFi Abs. Reductions of acute anterior uveitis have been found with etanercept but less impressively than adalimumab, infliximab, and in my opinion less than golimumab and certolizumab pegol.
Read Article
This article was originally published March 17, 2025, and is being shared again this week as part of our In Case You Missed It series. Enjoy!
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
